Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N

Cancer Gene Therapy

Volumn 10, Issue 1, 2003, Pages 40-48

  McCarthy, Helen O ^a   Yakkundi, Anita ^a   McErlane, Verna ^a   Hughes, Clara M ^a   Keilty, Gillian ^a   Murray, Margaret ^a   Patterson, Laurence H ^b   Hirst, David G ^a   McKeown, Stephanie R ^a   Robson, Tracy ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AQ4N; Bioreductive prodrug; CYP3A4; Cytochrome P450; GDEPT; Radiation

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; CYTOCHROME REDUCTASE; DNA; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CELL DEATH; CELL HYPOXIA; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG METABOLISM; DRUG RESEARCH; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSFECTION; IN VITRO STUDY; MAMMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BLOTTING, WESTERN; CELL HYPOXIA; COMBINED MODALITY THERAPY; COMET ASSAY; CYTOCHROME P-450 ENZYME SYSTEM; DNA DAMAGE; DNA, NEOPLASM; FIBROSARCOMA; GENE THERAPY; HUMANS; MICE; MICE, INBRED C3H; NADPH-FERRIHEMOPROTEIN REDUCTASE; PRODRUGS; RADIATION DOSAGE; TRANSFECTION; TUMOR STEM CELL ASSAY;

ANIMALIA; MAMMALIA; MURINAE;

EID: 0037279816     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700522     Document Type: Article

References (38)

1. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 2001;187:22-36.
2. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature. 1997;389:239-242.
3. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P - 450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995;55:581-589.
4. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 1996;56:1331-1340.
5. Kan O, Griffiths L, Baban D, et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme pro-drug therapy of cancer. Cancer Gene Ther. 2001;8:473-482.
6. Griffiths L, Binley K, Iqball S, et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 2000;7:255-262.
7. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 2000;60:3761-3769.
8. Hejmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH, Hirst DG. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996;73:499-505.
9. Patterson LH, McKeown SR, Ruparelia K, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer. 2000;82:1984-1990.
10. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
11. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer. 1995;72:76-81.
12. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl. 1996;27:S39-S42.
13. Friery OP, Gallagher R, Murray MM, et al. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer. 2000;82:1469-1473.
14. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer. 2000;83:1589-1593.
15. Gallagher R, Hughes CM, Murray MM, et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer. 2001;85:625-629.
16. Smith PJ, Desnoyers R, Blunt N, Giles Y, Patterson LH, Watson JV. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry. 1997;27:43-53.
17. Wilson WR, Denny WA, Pullen SM, et al. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer Suppl. 1996;27:S43-S47.
18. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 1993;12:119-134.
19. Raleigh SM, Wanogho E, Burke MD, Patterson LH. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica. 1999;29:1115-1122.
20. Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys. 1998;42:763-767.
21. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 1997;57:4830-4837.
22. Ding S, Yao D, Burchell B, Wolf CR, Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys. 1997;348:403-410.
23. Twentyman PR. Comparative chemosensitivity of exponentialversus plateau-phase cells in both in vitro model systems. Cancer Treat Rep. 1976;60:1719-1722.
24. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-191.
25. McKelvey-Martin VJ, Green MH, Schmezer P, Pool-Zobel BL, DeMeo MP, Collins A. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res. 1993;288:47-63.
26. Swaine DJ, Loadman PM, Bibby MC, Graham MA, Patterson LH. High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide. J Chromatogr B Biomed Sci Appl. 2000;742:239-245.
27. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 1989;49:2344-2350.
28. Weber GF, Waxman DJ. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol. 1993;45:1685-1694.
29. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000;6:157-162.
30. Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999;14:473-486.
31. Hejmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH, Hirst DG. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996;73:499-505.
32. Smith PJ, Blunt NJ, Desnoyers R, Giles Y, Patterson LH. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol. 1997;39:455-461.
33. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302-8306.
34. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
35. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 1998;5:1705-1711.
36. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
37. Frank DK, Frederick MJ, Liu TJ, Clayman GL. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res. 1998;4:2521-2528.
38. Massaad L, deWaziers I, Ribrag V, et al. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res. 1992;52:6567-6575.